Trade Fulcrum Therapeutics, Inc. - FULC CFD
Market information is presented
as of 2023-09-21
- Summary
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Fulcrum Therapeutics Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 4.84 |
| Open* | 4.71 |
| 1-Year Change* | -4.07% |
| Day's Range* | 4.67 - 4.94 |
| 52 wk Range | 2.25-15.00 |
| Average Volume (10 days) | 1.33M |
| Average Volume (3 months) | 45.31M |
| Market Cap | 343.12M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 61.82M |
| Revenue | 3.04M |
| EPS | -1.81 |
| Dividend (Yield %) | N/A |
| Beta | 2.05 |
| Next Earnings Date | Nov 6, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jun 29, 2022 | 4.91 | 0.20 | 4.25% | 4.71 | 4.97 | 4.65 |
| Jun 28, 2022 | 4.84 | -0.30 | -5.84% | 5.14 | 5.14 | 4.78 |
| Jun 27, 2022 | 5.19 | 0.18 | 3.59% | 5.01 | 5.25 | 4.86 |
| Jun 24, 2022 | 5.12 | 0.14 | 2.81% | 4.98 | 5.21 | 4.90 |
| Jun 23, 2022 | 5.07 | 0.30 | 6.29% | 4.77 | 5.11 | 4.77 |
| Jun 22, 2022 | 4.88 | 0.50 | 11.42% | 4.38 | 5.12 | 4.38 |
| Jun 21, 2022 | 4.46 | -0.15 | -3.25% | 4.61 | 4.90 | 4.46 |
| Jun 17, 2022 | 4.55 | 0.20 | 4.60% | 4.35 | 4.89 | 4.31 |
| Jun 16, 2022 | 4.34 | 0.23 | 5.60% | 4.11 | 4.41 | 4.05 |
| Jun 15, 2022 | 4.39 | 0.32 | 7.86% | 4.07 | 4.42 | 4.07 |
| Jun 14, 2022 | 4.23 | 0.16 | 3.93% | 4.07 | 4.40 | 3.97 |
| Jun 13, 2022 | 4.15 | -0.42 | -9.19% | 4.57 | 4.62 | 4.11 |
| Jun 10, 2022 | 4.89 | -0.12 | -2.40% | 5.01 | 5.18 | 3.19 |
| Jun 9, 2022 | 8.07 | 0.09 | 1.13% | 7.98 | 8.41 | 7.89 |
| Jun 8, 2022 | 8.26 | 0.58 | 7.55% | 7.68 | 8.59 | 7.68 |
| Jun 7, 2022 | 8.04 | 0.68 | 9.24% | 7.36 | 8.31 | 7.35 |
| Jun 6, 2022 | 7.52 | -0.59 | -7.27% | 8.11 | 8.46 | 7.48 |
| Jun 3, 2022 | 7.93 | 0.65 | 8.93% | 7.28 | 8.02 | 7.28 |
| Jun 2, 2022 | 7.51 | 0.86 | 12.93% | 6.65 | 7.93 | 6.65 |
| Jun 1, 2022 | 6.87 | -0.19 | -2.69% | 7.06 | 7.24 | 6.55 |
Fulcrum Therapeutics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, November 6, 2023 | ||
| Time (UTC) 13:30 | Country US
| Event Q3 2023 Fulcrum Therapeutics Inc Earnings Release Q3 2023 Fulcrum Therapeutics Inc Earnings ReleaseForecast -Previous - |
| Thursday, March 7, 2024 | ||
| Time (UTC) 13:30 | Country US
| Event Q4 2023 Fulcrum Therapeutics Inc Earnings Release Q4 2023 Fulcrum Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 6.342 | 19.163 | 8.823 | 0 | 0 |
| Total Operating Expense | 118.903 | 100.217 | 80.434 | 84.217 | 33.498 |
| Selling/General/Admin. Expenses, Total | 41.694 | 30.516 | 21.392 | 13.145 | 8.314 |
| Research & Development | 76.782 | 69.701 | 59.042 | 71.072 | 25.184 |
| Operating Income | -112.561 | -81.054 | -71.611 | -84.217 | -33.498 |
| Interest Income (Expense), Net Non-Operating | 1.511 | 0.518 | |||
| Other, Net | 2.69 | 0.207 | 0.792 | 0.029 | 0.392 |
| Net Income Before Taxes | -109.871 | -80.847 | -70.819 | -82.677 | -32.588 |
| Net Income After Taxes | -109.871 | -80.847 | -70.819 | -82.677 | -32.588 |
| Net Income Before Extra. Items | -109.871 | -80.847 | -70.819 | -82.677 | -32.588 |
| Net Income | -109.871 | -80.847 | -70.819 | -82.677 | -32.588 |
| Total Adjustments to Net Income | 0 | -7.128 | -6.559 | ||
| Income Available to Common Excl. Extra. Items | -109.871 | -80.847 | -70.819 | -89.805 | -39.147 |
| Income Available to Common Incl. Extra. Items | -109.871 | -80.847 | -70.819 | -89.805 | -39.147 |
| Diluted Net Income | -109.871 | -80.847 | -70.819 | -89.805 | -39.147 |
| Diluted Weighted Average Shares | 44.991 | 35.361 | 25.354 | 22.6544 | 22.2934 |
| Diluted EPS Excluding Extraordinary Items | -2.44207 | -2.28633 | -2.79321 | -3.96412 | -1.75599 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| Diluted Normalized EPS | -2.43258 | -2.28633 | -2.79321 | -3.96412 | -1.75599 |
| Revenue | 6.342 | 19.163 | 8.823 | ||
| Unusual Expense (Income) | 0.427 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0.88 | 0.295 | 0.685 | 1.183 | 1.882 |
| Revenue | 0.88 | 0.295 | 0.685 | 1.183 | 1.882 |
| Total Operating Expense | 28.172 | 28.235 | 28.658 | 25.538 | 36.117 |
| Selling/General/Admin. Expenses, Total | 10.323 | 11.52 | 10.13 | 9.707 | 11.098 |
| Research & Development | 17.849 | 16.715 | 18.566 | 15.366 | 25.019 |
| Operating Income | -27.292 | -27.94 | -27.973 | -24.355 | -34.235 |
| Other, Net | 3.509 | 3.161 | 1.838 | 0.617 | 0.165 |
| Net Income Before Taxes | -23.783 | -24.779 | -26.135 | -23.738 | -34.07 |
| Net Income After Taxes | -23.783 | -24.779 | -26.135 | -23.738 | -34.07 |
| Net Income Before Extra. Items | -23.783 | -24.779 | -26.135 | -23.738 | -34.07 |
| Net Income | -23.783 | -24.779 | -26.135 | -23.738 | -34.07 |
| Income Available to Common Excl. Extra. Items | -23.783 | -24.779 | -26.135 | -23.738 | -34.07 |
| Income Available to Common Incl. Extra. Items | -23.783 | -24.779 | -26.135 | -23.738 | -34.07 |
| Diluted Net Income | -23.783 | -24.779 | -26.135 | -23.738 | -34.07 |
| Diluted Weighted Average Shares | 61.794 | 59.722 | 52.155 | 46.213 | 40.89 |
| Diluted EPS Excluding Extraordinary Items | -0.38488 | -0.41491 | -0.5011 | -0.51366 | -0.83321 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.38488 | -0.41491 | -0.50183 | -0.5036 | -0.83321 |
| Unusual Expense (Income) | -0.038 | 0.465 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 207.519 | 225.998 | 119.51 | 100.083 | 74.095 |
| Cash and Short Term Investments | 202.921 | 218.162 | 112.914 | 96.713 | 72.797 |
| Cash & Equivalents | 35.098 | 35.412 | 57.052 | 96.713 | 72.797 |
| Total Receivables, Net | 1.081 | 4.11 | 2.707 | 0.111 | 0.501 |
| Accounts Receivable - Trade, Net | 1.081 | 4.11 | 2.707 | 0.111 | 0.135 |
| Prepaid Expenses | 3.517 | 3.726 | 3.815 | 2.975 | 0.559 |
| Other Current Assets, Total | 0 | 0.074 | 0.284 | 0.238 | |
| Total Assets | 226.685 | 235 | 129.577 | 110.439 | 85.771 |
| Property/Plant/Equipment, Total - Net | 15.969 | 7.368 | 8.397 | 9.205 | 10.546 |
| Property/Plant/Equipment, Total - Gross | 26.631 | 15.637 | 14.515 | 13.152 | 12.504 |
| Accumulated Depreciation, Total | -10.662 | -8.269 | -6.118 | -3.947 | -1.958 |
| Other Long Term Assets, Total | 3.197 | 1.634 | 1.67 | 1.151 | 1.13 |
| Total Current Liabilities | 16.725 | 19.199 | 26.725 | 12.14 | 4.229 |
| Accounts Payable | 3.638 | 4.788 | 4.079 | 2.186 | 1.263 |
| Accrued Expenses | 12.048 | 9.157 | 7.212 | 5.397 | 2.157 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.017 | 0.05 | 0.046 | |
| Other Current Liabilities, Total | 1.039 | 5.254 | 15.417 | 4.507 | 0.763 |
| Total Liabilities | 27.743 | 23.461 | 34.396 | 23.286 | 9.771 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 11.018 | 4.262 | 7.671 | 11.146 | 5.542 |
| Total Equity | 198.942 | 211.539 | 95.181 | 87.153 | 76 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 139.67 | ||
| Common Stock | 0.052 | 0.041 | 0.028 | 0.023 | 0.011 |
| Additional Paid-In Capital | 612.025 | 514.362 | 316.775 | 237.931 | 4.443 |
| Retained Earnings (Accumulated Deficit) | -412.338 | -302.467 | -221.62 | -150.801 | -68.124 |
| Treasury Stock - Common | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities & Shareholders’ Equity | 226.685 | 235 | 129.577 | 110.439 | 85.771 |
| Total Common Shares Outstanding | 52.0992 | 40.6262 | 27.9416 | 22.6544 | 22.2934 |
| Short Term Investments | 167.823 | 182.75 | 55.862 | ||
| Other Equity, Total | -0.797 | -0.397 | -0.002 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 302.83 | 207.519 | 227.727 | 174.247 | 200.064 |
| Cash and Short Term Investments | 297.84 | 202.921 | 221.789 | 168.973 | 195.112 |
| Cash & Equivalents | 34.734 | 35.098 | 90.938 | 40.153 | 33.313 |
| Short Term Investments | 263.106 | 167.823 | 130.851 | 128.82 | 161.799 |
| Total Receivables, Net | 1.264 | 1.081 | 1.237 | 1.492 | 1.208 |
| Accounts Receivable - Trade, Net | 1.264 | 1.081 | 1.237 | 1.492 | 1.208 |
| Prepaid Expenses | 3.726 | 3.517 | 4.701 | 3.782 | 3.697 |
| Other Current Assets, Total | 0.047 | ||||
| Total Assets | 321.12 | 226.685 | 247.805 | 195.233 | 220.248 |
| Property/Plant/Equipment, Total - Net | 15.167 | 15.969 | 16.888 | 17.788 | 18.276 |
| Property/Plant/Equipment, Total - Gross | 26.395 | 26.631 | 26.959 | 27.248 | 27.067 |
| Accumulated Depreciation, Total | -11.228 | -10.662 | -10.071 | -9.46 | -8.791 |
| Other Long Term Assets, Total | 3.123 | 3.197 | 3.19 | 3.198 | 1.908 |
| Total Current Liabilities | 14.407 | 16.725 | 14.699 | 22.121 | 18.288 |
| Accounts Payable | 3.778 | 3.638 | 2.728 | 5.385 | 6.003 |
| Accrued Expenses | 9.883 | 12.048 | 10.557 | 14.943 | 9.231 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Other Current Liabilities, Total | 0.746 | 1.039 | 1.414 | 1.793 | 3.054 |
| Total Liabilities | 24.864 | 27.743 | 26.391 | 34.478 | 31.088 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 10.457 | 11.018 | 11.692 | 12.357 | 12.8 |
| Total Equity | 296.256 | 198.942 | 221.414 | 160.755 | 189.16 |
| Common Stock | 0.062 | 0.052 | 0.052 | 0.041 | 0.041 |
| Additional Paid-In Capital | 733.962 | 612.025 | 608.486 | 524.247 | 518.604 |
| Retained Earnings (Accumulated Deficit) | -437.117 | -412.338 | -386.203 | -362.465 | -328.395 |
| Treasury Stock - Common | 0 | 0 | 0 | 0 | |
| Other Equity, Total | -0.651 | -0.797 | -0.921 | -1.068 | -1.09 |
| Total Liabilities & Shareholders’ Equity | 321.12 | 226.685 | 247.805 | 195.233 | 220.248 |
| Total Common Shares Outstanding | 61.759 | 52.0992 | 52.0499 | 41.0082 | 40.6836 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -109.872 | -80.847 | -70.819 | -82.677 | -32.588 |
| Cash From Operating Activities | -97.05 | -78.478 | -53.655 | -39.483 | -22.562 |
| Cash From Operating Activities | 2.414 | 2.515 | 2.379 | 2.053 | 1.345 |
| Non-Cash Items | 13.502 | 11.743 | 7.282 | 29.815 | 2.159 |
| Cash Interest Paid | 0 | 0 | 0.004 | 0.007 | 0.01 |
| Changes in Working Capital | -3.094 | -11.889 | 7.503 | 11.326 | 6.522 |
| Cash From Investing Activities | 12.413 | -129.669 | -57.138 | -0.944 | -8.981 |
| Capital Expenditures | -1.963 | -1.713 | -1.342 | -0.853 | -8.981 |
| Cash From Financing Activities | 84.323 | 186.507 | 71.132 | 64.343 | 105.025 |
| Issuance (Retirement) of Stock, Net | 84.323 | 186.525 | 71.375 | 0.215 | 105.095 |
| Issuance (Retirement) of Debt, Net | 0 | -0.018 | -0.05 | -0.045 | -0.07 |
| Net Change in Cash | -0.314 | -21.64 | -39.661 | 23.916 | 73.482 |
| Other Investing Cash Flow Items, Total | 14.376 | -127.956 | -55.796 | -0.091 | |
| Financing Cash Flow Items | -0.193 | 64.173 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -24.779 | -109.872 | -83.736 | -59.998 | -25.928 |
| Cash From Operating Activities | -24.116 | -97.05 | -77.354 | -49.472 | -22.106 |
| Cash From Operating Activities | 0.566 | 2.414 | 1.823 | 1.212 | 0.536 |
| Non-Cash Items | 2.887 | 13.502 | 10.832 | 7.367 | 4.2 |
| Cash Interest Paid | 0 | ||||
| Changes in Working Capital | -2.79 | -3.094 | -6.273 | 1.947 | -0.914 |
| Cash From Investing Activities | -93.941 | 12.413 | 48.775 | 51.054 | 19.659 |
| Capital Expenditures | -0.171 | -1.963 | -1.847 | -1.564 | -0.246 |
| Other Investing Cash Flow Items, Total | -93.77 | 14.376 | 50.622 | 52.618 | 19.905 |
| Cash From Financing Activities | 117.693 | 84.323 | 84.105 | 3.159 | 0.348 |
| Issuance (Retirement) of Stock, Net | 117.693 | 84.323 | 84.105 | 3.159 | 0.348 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
| Net Change in Cash | -0.364 | -0.314 | 55.526 | 4.741 | -2.099 |
| Financing Cash Flow Items |
Fulcrum Therapeutics, Inc. Company profile
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc. clinical-stage biopharmaceutical company. The Company focuses on improving the lives of patients with genetically defined rare diseases. The Company have developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The Company is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders. The Company is using Its proprietary product engine to identify and validate drug targets and develop product candidates to address diseases caused by the mis-expression of certain genes. Its product candidate includes losmapimod, is a small molecule that is developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, is a small molecule designed to bind embryonic ectoderm development (EED).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Fulcrum Therapeutics Inc revenues increased from $8.8M to $19.2M. Net loss increased 14% to $80.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 17% to $65.2M (expense), General and administrative increase of 37% to $23.9M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
26 Landsdowne Street
CAMBRIDGE
MASSACHUSETTS 02139
US
News
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com